Engflag

Clopex Agrel

Quick links to important sections

Clopex Agrel

Clopex Agrel_EN

Method of action: Antiplatelet, Antithrombotic

Treatment option: Coronary Artery Bypass Graft, Peripheral Arterial Disease, Cerebrovascular Accident, Accelerating Angina, Acute Coronary Syndrome, Heart Attack, Angina Pectoris

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clopex Agrel

What is Clopex Agrel?

Clopex Agrel is a pharmaceutical formulation containing the active ingredient clopidogrel. It belongs to a class of medications known as P2Y12 inhibitors, which are specialized antiplatelet agents. This medication is primarily utilized to influence how blood cells interact with one another to maintain circulatory flow.

Mechanism of Action

The primary function of Clopex Agrel is to prevent platelets from adhering to one another. Platelets are small blood cells that normally initiate the clotting process when a blood vessel is injured. However, in certain medical conditions, these cells can aggregate unnecessarily inside the arteries, potentially leading to the formation of thrombi (blood clots).

By selectively inhibiting the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor, Clopex Agrel prevents the subsequent activation of the glycoprotein IIb/IIIa complex. This action reduces the likelihood of platelet aggregation, thereby assisting in the prevention of vascular events.

Clinical Applications

Clopex Agrel is typically prescribed for individuals who have a history of cardiovascular or cerebrovascular conditions. Its use is generally focused on long-term management in the following contexts:

  • Recent Myocardial Infarction: For individuals who have recently experienced a heart attack.
  • Recent Ischemic Stroke: For those with a history of stroke caused by blood flow obstruction.
  • Established Peripheral Arterial Disease: To manage blood flow in individuals with narrowing of the arteries in the limbs.
  • Acute Coronary Syndrome: Used as part of a management strategy for patients experiencing unstable angina or specific types of heart attacks.

Role in Cardiovascular Health

Unlike anticoagulants (such as heparin or warfarin) which target clotting factors in the blood plasma, Clopex Agrel targets the cellular component of the blood. By modifying platelet behavior, it serves as a foundational component in the management of atherothrombosis, a condition characterized by the sudden rupture of an atherosclerotic plaque leading to clot formation.

Regulatory References

  1. Clopidogrel: MedlinePlus Drug Information

What side effects are possible with Clopex Agrel?

Possible Side Effects and Safety Information

The safety profile of Clopex Agrel (Clopidogrel) is officially defined by regulatory authorities based on the drug's antiplatelet action, with the primary concern being the risk of bleeding.

Adverse Reactions by Frequency and System-Organ Class

The official labeling organizes adverse events by frequency, which range from common to very rare, and groups them by the body system affected (System-Organ Class or SOC):

  • Common Reactions (affecting 1% to 10% of patients) often involve the Gastrointestinal System (e.g., diarrhea, abdominal pain, dyspepsia) and Vascular Disorders (e.g., epistaxis or nosebleeds, hematoma, and bruising).
  • Uncommon Reactions (affecting 0.1% to 1%) include gastrointestinal ulcers and gastritis, as well as dermatological effects like rash and pruritus.
  • Very Rare Reactions (affecting less than 0.01%) include severe systemic concerns such as Acquired Haemophilia and Thrombotic Thrombocytopenic Purpura (TTP).

Serious Safety Constraints

The most significant documented risks are major hemorrhage, including life-threatening and fatal Intracranial and Gastrointestinal bleeding. TTP is a rare, severe condition noted in regulatory warnings that may occur, sometimes after short exposure to the medicine. The medicine is contraindicated in patients with an active pathological bleed (e.g., active peptic ulcer) and known hypersensitivity to the drug substance. Safety considerations also exist for individuals classified as CYP2C19 poor metabolizers, who may have a diminished antiplatelet response.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Clopex Agrel (clopidogrel) primarily results in the exaggeration of its antiplatelet effect, leading to a significant prolongation of bleeding time. Immediate emergency medical help is mandated upon any suspicion of overdose, as per official regulatory guidance.

Overdose Manifestations Severe Outcomes
Exaggerated bleeding time Major bleeding events
Unusual bruising or bleeding Life-threatening hemorrhage
Bleeding complications Intracranial hemorrhage

Emergency Actions and Treatment

  • When to Seek Help: If an overdose is suspected, seek immediate medical attention or call emergency services (e.g., Poison Control) right away.
  • No Specific Antidote: Regulatory documents explicitly state that no specific antidote is known to reverse the pharmacological activity of clopidogrel.
  • Treatment Approach: Treatment must be symptomatic and supportive, focusing on managing the bleeding complications. In cases of severe, life-threatening bleeding, platelet transfusion may be considered to help restore clotting ability.
  • Monitoring: Hospital monitoring is often required, including close observation of clinical status and laboratory testing to assess coagulation parameters and the degree of bleeding risk.

The regulatory profile defines overdose by the risk of excessive bleeding, which is the direct result of the drug's antiplatelet activity. This severe hemorrhagic risk mandates that patients seek immediate medical attention for suspected overexposure. Emergency care focuses on supportive measures and observation to manage potential bleeding complications due to the officially documented absence of a specific antidote.

Therapeutic Uses of Clopex Agrel

What Clopex Agrel Treats: Main Uses and Benefits

Clopex Agrel is commonly used to help reduce the risk of major atherothrombotic events—problems associated with the development of vascular obstruction—in patients at significant risk. It is relevant across conditions characterized by periods of heightened symptoms, including management for Acute Coronary Syndrome, long-term secondary prevention following a recent Myocardial Infarction or Ischemic Stroke, and supportive care for established Peripheral Arterial Disease (PAD).

This approach is designed to help provide sustained support to the patient in situations involving certain distressing symptoms. Its sustained use assists with maintaining functional stability and offers symptomatic relief that helps patients cope more steadily with the ongoing risk of recurrent cardiovascular events. By addressing the risk of problematic clotting, Clopex Agrel provides supportive relief when a patient is experiencing heightened systemic burden from a vascular threat. This assists with maintaining functional stability against further vascular impairment.

Quick Fact: Relief for Vascular Risk
Common Use Contexts: Secondary prevention after heart attack or stroke, management during Acute Coronary Syndrome, and support following coronary stenting.
Patient Benefit: Contributes to easing the overall symptom load by contributing to a reduction in the risk of serious, acute vascular obstruction.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Clopex Agrel is generally permitted for adult patients with established vascular conditions, but eligibility is subject to strict limitations and absolute contraindications defined in regulatory documents.

Absolute Contraindications (Must Not Use)

Official labeling strictly prohibits the use of this medicine in patients with:

  • Active pathological bleeding, such as from a peptic ulcer or intracranial hemorrhage.
  • Known severe hepatic impairment (severe liver disease).
  • Documented hypersensitivity to clopidogrel or any component of the product.

Restricted and Conditional Use

Population Category Regulatory Status
Pediatric Patients (Children/Adolescents) Use is not recommended; safety and efficacy have not been established.
Organ Function Caution is required for patients with renal impairment or moderate hepatic disease due to limited clinical data.
Metabolic Status Patients identified as CYP2C19 poor metabolizers may have diminished antiplatelet response.
Pregnancy/Lactation Use is generally not recommended; the drug is associated with increased risk of maternal hemorrhage during labor and delivery.
Procedural Restriction The drug must be discontinued 5 to 7 days prior to elective surgery.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clopex Agrel's official interaction profile is defined by its requirement for metabolic activation and its antiplatelet activity, as detailed in regulatory documents.

Classification Official Regulatory Statement
Pharmacokinetic Inhibition Concomitant use with omeprazole or esomeprazole is discouraged due to their ability to inhibit CYP2C19, an enzyme required to form the active metabolite, thereby reducing its antiplatelet effect. Other strong CYP2C19 inhibitors should also be avoided.
Pharmacokinetic Induction Co-administration of strong CYP2C19 inducers like Rifampin is expected to increase active metabolite levels, potentially increasing the risk of bleeding [FDA].
Pharmacodynamic Interaction Co-administration with Oral Anticoagulants (e.g., Warfarin), NSAIDs, or other Antiplatelet Agents (e.g., Aspirin) is not recommended or requires caution, as these combinations increase the risk and intensity of bleeding due to additive effects on hemostasis [EMA].
Non-Metabolic Interference Co-administration with Opioid Agonists (e.g., Morphine) delays and reduces the absorption of Clopex Agrel, resulting in reduced exposure to the active antiplatelet metabolite.
Inhibition of CYP2C8 The active metabolite of Clopex Agrel is a strong inhibitor of the CYP2C8 enzyme, which increases the plasma concentration of medicines that are substrates for this enzyme, such as Repaglinide [FDA].

Regulatory Context and Constraints

For elective surgery that carries a major risk of bleeding, official labeling requires that Clopex Agrel be discontinued 5 to 7 days prior to the procedure. Additionally, patients identified as CYP2C19 Poor Metabolizers are noted to form less of the active metabolite, resulting in a diminished antiplatelet response, a genetic factor that affects the impact of metabolic drug interactions.

Mechanism of Action

Irreversible Blockade of the Platelet P2Y12 Receptor

The core mechanism involves Clopex Agrel's active metabolite permanently disabling the P2Y12 receptor on the surface of circulating platelets. This P2 Y12 receptor is the critical gateway for signals (specifically ADP) that trigger platelet aggregation. The binding is irreversible because the active metabolite forms a covalent bond with the receptor protein, a permanent modification lasting for the sim 7-10 day lifespan of the treated platelet. This action produces a sustained alteration in the sensitivity of platelets to aggregating signals.

Disruption of the Platelet Activation Cascade

By blocking the P2 Y12 receptor, the drug prevents the necessary molecular cascade for platelets to initiate adhesion. This antagonism sustains high levels of internal cAMP within the platelet, which functions as an endogenous signal to suppress activation. This physiological dampening ultimately prevents the activation of the final binding structure, the GPIIb/IIIa complex , resulting in decreased ability of platelets to cross-link and aggregate systemically.

Mechanism Constrained by Prodrug Activation

Clopex Agrel is an inactive prodrug that must undergo mandatory biotransformation in the liver to yield the active metabolite. This process depends heavily on specific liver enzymes, primarily CYP2C19. Because of this requirement, the full antiplatelet effect is subject to a time lag until sufficient active metabolite is produced. Furthermore, genetic variations in the CYP2C19 enzyme can lead to reduced conversion, which results in mechanistically constrained active metabolite formation and subsequently reduced P2Y12 receptor occupancy.

Dosage and Administration Information

How to Use Clopex Agrel

Clopex Agrel, which contains the active ingredient Clopidogrel, is a prescription-only medicine provided as film-coated tablets and approved solely for oral administration. The correct method of taking this medicine involves specific official dosing schedules and procedural rules, which must be followed precisely as directed by healthcare professionals.

Official Dosing and Administration

Administration Detail Official Description
Administration Route Oral
Standard Strengths 75 mg and 300 mg tablets
Timing with Meals Can be taken with or without food

The standard approach to using Clopex Agrel is to take the prescribed dose once daily (qDay). In certain acute conditions, such as Acute Coronary Syndrome, treatment is initiated with a single, higher dose, known as a loading dose—typically 300 mg—to quickly establish the desired antiplatelet effect, followed by the maintenance dose of 75 mg daily.

Duration and Population-Specific Rules

Treatment with Clopex Agrel for conditions like recent myocardial infarction (MI) or stroke is generally long-term. The optimal duration for dual antiplatelet therapy may vary but is often continued for up to 12 months following an acute event.

Special Instructions:

  • Missed Dose: If less than 12 hours have passed since the scheduled time, the missed dose should be taken immediately. If more than 12 hours have passed, skip the missed dose and resume the usual schedule; do not double the dose.
  • Older Adults: For patients over 75 years of age with ST-Elevation MI, the medicine should be initiated without a loading dose.
  • Discontinuation: The medicine must be temporarily stopped 5 to 7 days before elective surgery with a high risk of bleeding, as advised by the supervising physician.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clopex Agrel

Evidence for Use in Acute Coronary Syndrome (ACS) Management

Clopex Agrel was studied in large-scale Randomized Controlled Trials (RCTs) for adult patients experiencing Acute Coronary Syndrome. Research examined the medicine's role, typically combined with aspirin, focusing on outcomes such as Cardiovascular Death, Myocardial Infarction, and Stroke over short- and intermediate-term follow-up periods. Research describes the rates of these events that were measured in comparison to other observed treatment patterns.

Evidence for Secondary Prevention of Atherothrombotic Events

Research for this use was evaluated in long-term comparative trials, observing adult populations with established vascular diseases (history of MI, Stroke, or PAD) for five years or more. These studies examined outcomes measuring the composite rate of Vascular Death, non-fatal Myocardial Infarction, and Stroke recurrence. Data show patterns related to these events measured in the monotherapy trials.

Adjunctive Therapy Following Coronary Intervention

Clopex Agrel was studied as part of a dual antiplatelet regimen following Percutaneous Coronary Intervention (PCI) or coronary stenting. The research examined specific outcomes related to the procedure, such as the rate of Stent Thrombosis and re-hospitalization for Myocardial Infarction, with findings describing patterns observed in these procedural outcomes.

Research Gaps and Unresolved Questions

Despite extensive data, the certainty for use in neonates and infants with complex cardiac conditions remains low, as clinical analysis found trial findings were mixed and inconclusive. Additionally, a core area of uncertainty surrounds genetic variability (CYP2C19), which may cause differences in how effectively an individual patient processes the medicine. Long-term effects are not fully established beyond the core trial durations, and data for certain subgroups remain limited.

Key Studies & References

  1. FDA Drug Label for Plavix (Clopidogrel Bisulfate) - Warning on Diminished Antiplatelet Effect (CYP2C19)

Frequently Asked Questions (FAQ)

Common questions about Clopex Agrel (FAQ)

Q: What is Clopex Agrel used for?

A: Clopex Agrel is indicated for the reduction of atherosclerotic events, such as myocardial infarction and stroke, in patients who have a history of recent stroke, recent myocardial infarction, or established peripheral arterial disease. Its use should be determined by a healthcare provider.

Q: How does Clopex Agrel work?

A: Clopex Agrel is in a class of medications called antiplatelet agents. It works by preventing platelets from adhering to one another and forming harmful blood clots in the arteries. This mechanism helps to improve blood flow.

Q: Is Clopex Agrel effective?

A: Clinical trials have demonstrated that Clopex Agrel is associated with a lower rate of cardiovascular events compared to placebo in high-risk patients. The level of effectiveness may vary among individuals.

Q: Are there any common side effects of Clopex Agrel?

A: The most frequently reported side effects observed in clinical studies include bleeding (such as bruising or nosebleeds), headache, and stomach upset. It is important to discuss all potential side effects and health concerns with your healthcare provider.

Q: Can Clopex Agrel be taken with other medications?

A: Clopex Agrel may interact with certain other medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, and other anti-clotting agents. It is necessary to inform your healthcare provider about all prescription and non-prescription products you are taking before starting treatment with Clopex Agrel.

How should Clopex Agrel be stored and disposed of?

How to Store Clopex Agrel

Clopex Agrel tablets must be stored according to specific regulatory requirements to maintain product stability and quality. The medication should be kept at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). The official labeling mandates that the tablets be protected from moisture and light; therefore, the product must remain in its original container and the container must be kept tightly closed.

Child Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children. When disposing of unused or expired Clopex Agrel, do not throw the product in household trash or flush it down the toilet. Instead, follow local instructions for proper disposal, such as utilizing a community drug take-back program or pharmacy collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagEgypt

Equivalent of Clopex Agrel found in:

A-Z Index: